Reversible cholinesterase inhibitors as pretreatment for exposure to organophosphates. A review (2018)

Peer-Reviewed Study · Lorke DE, Petroianu GA · July 19, 2018

Lorke DE et al., 2018-07-19: Review of animal experiments testing reversible cholinesterase inhibitors as organophosphate pretreatment, in which methylene blue failed to protect against six organophosphates.

Tiapride, amiloride, metoclopramide, methylene blue and 7-methoxytacrine did not achieve protection.

Abstract

Lorke DE et al., 2018-07-19: Review of animal experiments testing reversible cholinesterase inhibitors as organophosphate pretreatment, in which methylene blue failed to protect against six organophosphates. Review of animal experiments; no human subjects. PMID 30027640; DOI 10.1002/jat.3662. Methylene blue is classed as a reversible acetylcholinesterase inhibitor, not a reactivator; it did not protect in the authors' standardised model. The paper credits oximes (K-27, obidoxime, pralidoxime) with reactivating activity, which is the mechanism the source attributes to methylene blue. Study type: review.